PT - JOURNAL ARTICLE AU - Rahul Y. Mahida AU - Joshua Price AU - Sebastian T. Lugg AU - Hui Li AU - Dhruv Parekh AU - Aaron Scott AU - Paul Harrison AU - Michael A. Matthay AU - David R. Thickett TI - CD14 Positive Extracellular Vesicles in Broncho-Alveolar Lavage Fluid as a New Biomarker of Acute Respiratory Distress Syndrome AID - 10.1101/2021.09.25.21264053 DP - 2021 Jan 01 TA - medRxiv PG - 2021.09.25.21264053 4099 - http://medrxiv.org/content/early/2021/09/28/2021.09.25.21264053.short 4100 - http://medrxiv.org/content/early/2021/09/28/2021.09.25.21264053.full AB - Recent studies have indicated that extracellular vesicles (EV) may play a role in the pathogenesis of Acute Respiratory Distress Syndrome (ARDS). EV have been identified as potential biomarkers of disease severity and prognosis in other pulmonary diseases. We sought to characterize the EV phenotype within ARDS patient broncho-alveolar lavage fluid (BAL), and to determine whether BAL EV could be utilized as a potential biomarker in ARDS. EV from the BAL of sepsis patients with ARDS, sepsis patients without ARDS, and post-operative control patients were characterized with regards to size, number and cell of origin. ARDS patients had significantly higher numbers of CD14+/CD81+ monocyte-derived BAL EV than sepsis patients without ARDS (p=0.022). CD14+/CD81+ BAL EV numbers were significantly higher in those ARDS patients who died during the 30 days following ICU admission (p=0.027). Also, across all sepsis patients there was an association between CD66b+/CD63+ neutrophil-derived BAL EV and increased BAL IL-8 concentration, increased alveolar neutrophil apoptosis and decreased alveolar macrophage efferocytosis. Thus, CD14+/CD81+ BAL EV are a potential biomarker for disease severity and mortality in ARDS. These findings provide the impetus to further elucidate the contribution of these EV to ARDS pathogenesis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by Medical Research Council grants MR/N021185/1 (RYM) and MR/L002736/1 (DT/AS), and by National Heart, Lung and Blood Institute grants HL134828 (MAM) and HL140026 (MAM). The ExoView platform was funded by an EPSRC Capital award awarded to Dr. Sophie Cox, University of Birmingham.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was given by the Wales Research Ethics Committee 1 (reference number 16/WA/0169) to recruit ventilated sepsis patients with and without ARDS. Ethical approval was also given by the South Birmingham (England) Research Ethics Committee (reference number 12/WM/0092) to recruit patients undergoing transthoracic esophagectomy for esophageal carcinoma as previously described in the VINDALOO trial. For patients who lacked capacity, permission to enroll was sought from a personal legal representative in accordance with the UK Mental Capacity Act (2005). For patients with capacity, written informed consent was obtained from the patient.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymised data are available upon reasonable request to the corresponding author.